METHOD FOR NEUTRALIZING HEPATITIS C VIRUS, FULLY HUMAN MONOCLONAL ANTIBODY AGAINST HEPATITIS C VIRUS (VARIANTS), COMPOSITION OF FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS AND HYBRID MOUSE/HUMAN PRODUCER CELL LINE OF FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS (VARIANTS)

The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology....

Full description

Saved in:
Bibliographic Details
Main Authors Sadgyan Armen Sergeevich, Rybalkin Igor Nikolaevich, Vlasik Tatiana Nikolaevna, Shevelev Alexandr Yasenovich
Format Patent
LanguageEnglish
Published 04.05.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to the field of biotechnology, and specifically to methods and techniques for neutralizing the hepatitis C virus, and specifically to antibodies against the hepatitis C virus, and can be used in medicine, the pharmaceutical industry and related areas of science and technology. Proposed is the use of fully human monoclonal antibodies-RYB1, RYB2 and RYB3-and of a composition based thereon for the prevention and treatment of hepatitis C. Said antibodies are produced by cultivation using hybrid BIONA-RYB1, BIONA-RYB2 and BIONA-RYB3. The effectiveness of the antibodies is due to said antibodies binding epitopes, namely Ep1, Ep2 and Ep3 of E2 protein of the hepatitis C viral envelope, respectively. The present invention has demonstrated a neutralizing activity of the antibodies in a model system of infection of human cells in a culture. It has been shown that use of the claimed group of inventions provides for more reliable antibody binding of the hepatitis C virus.
Bibliography:Application Number: US201415107996